\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ the\\ pt\\ will\\ receive\\ combination\\ radiation\\ and\\ chemotherapy\\.\\ \\ the\\ overall\\ 5\\ year\\ survival\\ for\\ hodgkin\\'s\\ disease\\ with\\ treatment\\ is\\ 82\\%\\.\\ \\ pet\\ scans\\ are\\ a\\ useful\\ means\\ of\\ staging\\ and\\ followup\\ to\\ determine\\ relapse\\.\\ \\ this\\ pt\\ has\\ received\\ a\\ pet\\ scan\\ which\\ will\\ be\\ entered\\ and\\ updated\\ soon\\.\ \(0\)\
\-\ \\â\\€\\¢\\ increased\\ densities\\ in\\ the\\ anterior\\ and\\ posterior\\ mediastinum\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ prevascular\\ lymph\\ node\\,\\ 1\\.7cm\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ peritracheal\\ lymph\\ node\\,\\ 1\\.6cm\ \(0\)\
\-\ \\â\\€\\¢\\ moderate\\ pericardial\\ effusion\ \(0\)\
\-\ classical\\ hodgkin\\'s\\ lymphoma\\,\\ nodular\\ sclerosing\\ type\ \(0\)\
\-\ \\â\\€\\¢\\ thymic\\ tumors\ \(0\)\
\-\ \\â\\€\\¢\\ pericardial\\ tumors\ \(0\)\
\-\ \\â\\€\\¢\\ mediastinal\\ carcinoids\ \(0\)\
\-\ \\â\\€\\¢\\ cystic\\ mediastinal\\ lesions\ \(0\)\
\-\ \\â\\€\\¢\\ thoracic\\ fungal\\ infections\ \(0\)\
\-\ \\â\\€\\¢\\ other\\ causes\\ of\\ lymphadenopathy\ \(0\)\
\-\ 21\\ year\\ old\\ man\\ with\\ a\\ 2\\ month\\ history\\ of\\ abdominal\\ pain\\,\\ weight\\ loss\\,\\ fevers\\,\\ and\\ chills\\.\ \(1\)\
\-\ \\â\\€\\¢lymphomas\\ are\\ divided\\ into\\ hodgkin\\â\\€\\™s\\ and\\ non\\-hodgkin\\â\\€\\™s\\.\ \(0\)\
\-\ \\â\\€\\¢hodgkin\\â\\€\\™s\\ lymphoma\\ is\\ characterized\\ by\\ reed\\-sternberg\\ cells\\,\\ with\\ 4\\ subtypes\\.\ \(0\)\
\-\ \\â\\€\\¢in\\ the\\ thorax\\,\\ nodular\\ sclerosing\\ is\\ the\\ most\\ common\\ subtype\\ with\\ a\\ predilection\\ for\\ the\\ mediastinum\\.\ \(0\)\
\-\ \\â\\€\\¢nodular\\ sclerosing\\ accounts\\ for\\ \\>50\\%\\ of\\ hodgkin\\â\\€\\™s\\ lymphomas\\.\ \(0\)\
\-\ \\â\\€\\¢frequency\\ \\-\\ in\\ the\\ us\\,\\ 7400\\ estimated\\ new\\ cases\\ in\\ 2001\ \(0\)\
\-\ \\â\\€\\¢bimodal\\ distribution\\ \\-\\ 15\\-40\\ years\\ old\\,\\ \\>55\\ years\\ old\ \(0\)\
\-\ \\â\\€\\¢treatment\\ consists\\ of\\ radiation\\ and\\/or\\ chemotherapy\ \(0\)\
\-\ \\â\\€\\¢survival\\ rates\\,\\ 1yr\\-93\\%\\,\\ 5yr\\-82\\%\\,\\ 10yr\\-72\\%\\,\\ 15yr\\-63\\%\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.09092326260683792\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.06696642528187555\ \(0\)\
\-\ sclerosing\\:\\ 0\\.06479895267016583\ \(0\)\
\-\ \\%\\:\\ 0\\.05111079572682071\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.04365857674607617\ \(0\)\
\-\ s\\:\\ 0\\.04189346439512115\ \(0\)\
\-\ pericardial\\:\\ 0\\.03928214289564438\ \(0\)\
\-\ pet\\:\\ 0\\.038331496441710834\ \(0\)\
\-\ peritracheal\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢lymphomas\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢hodgkin\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢in\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢nodular\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢frequency\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢bimodal\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢treatment\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ \\â\\€\\¢survival\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ 1yr\\-93\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ 5yr\\-82\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ 10yr\\-72\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ 15yr\\-63\\:\\ 0\\.03767315565797649\ \(0\)\
\-\ mediastinum\\:\\ 0\\.035171265454479336\ \(0\)\
\-\ 7400\\:\\ 0\\.03471098821968613\ \(0\)\
\-\ node\\:\\ 0\\.03342088585921427\ \(0\)\
\-\ reed\\-sternberg\\:\\ 0\\.03297823134742901\ \(0\)\
\-\ carcinoids\\:\\ 0\\.031748820781395765\ \(0\)\
\-\ 15\\-40\\:\\ 0\\.031748820781395765\ \(0\)\
\-\ mediastinal\\:\\ 0\\.031009680496801226\ \(0\)\
\-\ nodular\\:\\ 0\\.030635981257366766\ \(0\)\
\-\ prevascular\\:\\ 0\\.03001606390913865\ \(0\)\
\-\ lymph\\:\\ 0\\.02948326845251835\ \(0\)\
\-\ 1\\.6cm\\:\\ 0\\.02935730032013327\ \(0\)\
\-\ entered\\:\\ 0\\.028786653343105397\ \(0\)\
\-\ 1\\.7cm\\:\\ 0\\.028786653343105397\ \(0\)\
\-\ relapse\\:\\ 0\\.028283307036881533\ \(0\)\
\-\ lymphomas\\:\\ 0\\.0278330484229592\ \(0\)\
\-\ tumors\\:\\ 0\\.027433473142482918\ \(0\)\
\-\ pt\\:\\ 0\\.027155245766091903\ \(0\)\
\-\ updated\\:\\ 0\\.02671183361754257\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.02617902380462278\ \(0\)\
\-\ classical\\:\\ 0\\.02582448590481503\ \(0\)\
\-\ enlarged\\:\\ 0\\.024919838208410313\ \(0\)\
\-\ subtypes\\:\\ 0\\.024662376009585794\ \(0\)\
\-\ subtype\\:\\ 0\\.024662376009585794\ \(0\)\
\-\ non\\-hodgkin\\:\\ 0\\.02427360772665534\ \(0\)\
\-\ \\>\\:\\ 0\\.024266389014261237\ \(0\)\
\-\ predilection\\:\\ 0\\.024091729032557917\ \(0\)\
\-\ radiation\\:\\ 0\\.02396795939796869\ \(0\)\
\-\ thymic\\:\\ 0\\.02358838272633406\ \(0\)\
\-\ means\\:\\ 0\\.023138124112411722\ \(0\)\
\-\ divided\\:\\ 0\\.022997996664450224\ \(0\)\
\-\ accounts\\:\\ 0\\.022997996664450224\ \(0\)\
\-\ soon\\:\\ 0\\.022862318466524666\ \(0\)\
\-\ will\\:\\ 0\\.022850265114351644\ \(0\)\
\-\ 82\\:\\ 0\\.022603238886112553\ \(0\)\
\-\ receive\\:\\ 0\\.021501405085676228\ \(0\)\
\-\ years\\:\\ 0\\.02144652253861951\ \(0\)\
\-\ rates\\:\\ 0\\.021219533428446326\ \(0\)\
\-\ estimated\\:\\ 0\\.021129561594267557\ \(0\)\
\-\ staging\\:\\ 0\\.02104144498229005\ \(0\)\
\-\ lymphoma\\:\\ 0\\.02087349260161954\ \(0\)\
\-\ thorax\\:\\ 0\\.02070609619835204\ \(0\)\
\-\ densities\\:\\ 0\\.020247781966071705\ \(0\)\
\-\ consists\\:\\ 0\\.02003582922615986\ \(0\)\
\-\ survival\\:\\ 0\\.01957868341610786\ \(0\)\
\-\ 2001\\:\\ 0\\.01939680472201044\ \(0\)\
\-\ useful\\:\\ 0\\.01905474186870473\ \(0\)\
\-\ determine\\:\\ 0\\.018490948949719484\ \(0\)\
\-\ combination\\:\\ 0\\.018395978279699354\ \(0\)\
\-\ chills\\:\\ 0\\.018257365990155962\ \(0\)\
\-\ overall\\:\\ 0\\.01816739415597719\ \(0\)\
\-\ characterized\\:\\ 0\\.01816739415597719\ \(0\)\
\-\ fungal\\:\\ 0\\.01770380166454954\ \(0\)\
\-\ 55\\:\\ 0\\.01770380166454954\ \(0\)\
\-\ followup\\:\\ 0\\.017432991348598305\ \(0\)\
\-\ infections\\:\\ 0\\.017358667661795446\ \(0\)\
\-\ fevers\\:\\ 0\\.017358667661795446\ \(0\)\
\-\ scans\\:\\ 0\\.017005284260747953\ \(0\)\
\-\ received\\:\\ 0\\.016971501442341486\ \(0\)\
\-\ 21\\:\\ 0\\.016524609117898846\ \(0\)\
\-\ distribution\\:\\ 0\\.016434637283720077\ \(0\)\
\-\ \\,\\:\\ 0\\.016196328706162492\ \(0\)\
\-\ \\'s\\:\\ 0\\.016102962550145684\ \(0\)\
\-\ \\-\\:\\ 0\\.015655798792379178\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.015528781511429118\ \(0\)\
\-\ and\\/or\\:\\ 0\\.015433810841408987\ \(0\)\
\-\ us\\:\\ 0\\.015317990628683383\ \(0\)\
\-\ cells\\:\\ 0\\.014642934590384606\ \(0\)\
\-\ moderate\\:\\ 0\\.014359817558157252\ \(0\)\
\-\ causes\\:\\ 0\\.01421615682824706\ \(0\)\
\-\ thoracic\\:\\ 0\\.01407716882950535\ \(0\)\
\-\ 50\\:\\ 0\\.013893153917281218\ \(0\)\
\-\ effusion\\:\\ 0\\.013876811624809408\ \(0\)\
\-\ weight\\:\\ 0\\.01308951190231139\ \(0\)\
\-\ new\\:\\ 0\\.012725589644446832\ \(0\)\
\-\ type\\:\\ 0\\.012310359950200472\ \(0\)\
\-\ available\\:\\ 0\\.012276577131794007\ \(0\)\
\-\ cases\\:\\ 0\\.012165858393081763\ \(0\)\
\-\ old\\:\\ 0\\.011217110216182751\ \(0\)\
\-\ month\\:\\ 0\\.010955617695729102\ \(0\)\
\-\ 5\\:\\ 0\\.010684446249761384\ \(0\)\
\-\ loss\\:\\ 0\\.010600274241318118\ \(0\)\
\-\ cystic\\:\\ 0\\.010532618407058797\ \(0\)\
\-\ scan\\:\\ 0\\.010223382309542645\ \(0\)\
\-\ 4\\:\\ 0\\.010175093611876263\ \(0\)\
\-\ are\\:\\ 0\\.009956186944697451\ \(0\)\
\-\ lesions\\:\\ 0\\.009775899599760461\ \(0\)\
\-\ common\\:\\ 0\\.009556697486993152\ \(0\)\
\-\ anterior\\:\\ 0\\.009405097537447596\ \(0\)\
\-\ for\\:\\ 0\\.009347540367214297\ \(0\)\
\-\ abdominal\\:\\ 0\\.009127859991974853\ \(0\)\
\-\ increased\\:\\ 0\\.008933695648716478\ \(0\)\
\-\ into\\:\\ 0\\.00868942892290473\ \(0\)\
\-\ man\\:\\ 0\\.00863646086790598\ \(0\)\
\-\ most\\:\\ 0\\.008430919409094344\ \(0\)\
\-\ posterior\\:\\ 0\\.00841725875513867\ \(0\)\
\-\ other\\:\\ 0\\.00841725875513867\ \(0\)\
\-\ year\\:\\ 0\\.008171839908315512\ \(0\)\
\-\ 2\\:\\ 0\\.00786369442953225\ \(0\)\
\-\ treatment\\:\\ 0\\.0073915254683798596\ \(0\)\
\-\ is\\:\\ 0\\.0072088561331375076\ \(0\)\
\-\ has\\:\\ 0\\.006857692181599479\ \(0\)\
\-\ which\\:\\ 0\\.006816857210438243\ \(0\)\
\-\ a\\:\\ 0\\.006779483791770962\ \(0\)\
\-\ by\\:\\ 0\\.006080644885661859\ \(0\)\
\-\ disease\\:\\ 0\\.005968963851349164\ \(0\)\
\-\ be\\:\\ 0\\.00563143898864927\ \(0\)\
\-\ in\\:\\ 0\\.00540252859154173\ \(0\)\
\-\ not\\:\\ 0\\.005277002870692032\ \(0\)\
\-\ history\\:\\ 0\\.005043651870543092\ \(0\)\
\-\ and\\:\\ 0\\.004615615531595345\ \(0\)\
\-\ pain\\:\\ 0\\.004459863963806559\ \(0\)\
\-\ the\\:\\ 0\\.004135662362928977\ \(0\)\
\-\ this\\:\\ 0\\.004107423988521937\ \(0\)\
\-\ of\\:\\ 0\\.002489397452948471\ \(0\)\
\-\ with\\:\\ 0\\.0020000713861519615\ \(0\)\
\-\ to\\:\\ 0\\.0018250773865084884\ \(0\)\
\-\ \\.\\:\\ 0\\.0015170741921942852\ \(0\)\
